Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
about
Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Bortezomib-based induction imp ...... arboring 17p deletion and/or t
@nl
Bortezomib-based induction imp ...... comes their adverse prognosis.
@en
type
label
Bortezomib-based induction imp ...... arboring 17p deletion and/or t
@nl
Bortezomib-based induction imp ...... comes their adverse prognosis.
@en
prefLabel
Bortezomib-based induction imp ...... arboring 17p deletion and/or t
@nl
Bortezomib-based induction imp ...... comes their adverse prognosis.
@en
P2860
P1433
P1476
Bortezomib-based induction imp ...... comes their adverse prognosis.
@en
P2093
Amro M S El-Ghammaz
Essam Abdelwahed
P2860
P304
P356
10.1007/S00277-016-2692-0
P577
2016-05-16T00:00:00Z